Navigation Links
Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
Date:8/27/2009

diabetic person than in the general population. Among the patients with lower extremity amputation procedures, 5% to 17% will die during the operation and 2% to 30% will die within 30 days of surgery. Longer term survival is even worse. Mortality following amputation ranges from 13% to 40% at one year, 35% to 65% at 3 years and 39% to 80% at 5 years. These mortality rates are similar or worse than many common types of cancer including prostate, breast, colon and Hodgkin's disease. Despite these grim statistics, many remain unaware of the very serious nature of non-healing lower extremity ulcers in diabetic patients.

Innovative Advanced Care DNA-Based Therapy

Cardium's Excellarate(TM) product candidate is a collagen-based topical gel employing Tissue Repair Company's (TRC's) Gene Activated Matrix(TM) that is designed to locally stimulate the release of platelet-derived growth factor-B protein (PDGF-B), an important key in the human body's wound healing process. Sustained, localized micro-release of PDGF-B by a patient's own cells directly at the wound site is believed to stimulate angiogenesis and granulation tissue formation through the recruitment and proliferation of cells such as monocytes, fibroblasts and endothelial cells. These cell types are critical for the effective stimulation of a variety of wound healing processes.

Excellarate is an advanced care DNA-based biologic product candidate that is being developed to provide physicians and patients with a potentially simpler, easy-to-use treatment as compared to current therapies. Based on the positive data from a Phase1/2 study, the Company believes that the Excellarate topical gel provides a unique opportunity to: (1) improve patient compliance, based on a one or two physician administered treatment regimen, instead of current therapies which require multiple treatments by physicians or patients on a daily or weekly basis for up
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
2. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
3. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
4. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
5. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
6. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
7. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
8. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
9. Wyoming Department of Healths Pay-for-Participation Program Reports Positive Clinical Outcomes
10. Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
11. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  MiMedx Group, Inc. (NASDAQ: MDXG ), an ... and bioimplants processed from human amniotic membrane, announced today its ... Highlights include: , Revenue exceeds upper end ... $25.6 million , Quarter-over-quarter revenue grew ... increases 181% over Q2 2013 and 40% sequentially over Q1 ...
(Date:7/28/2014)... , July 28, 2014   Stone & ... of off-label marketing and fraud claims between the ... Solutions, Inc. ("VSI").  The settlement covers fraud in ... for endovenous laser ablation of varicose veins for ... firm with a history of representing whistleblowers in ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire-iReach/ -- June 28 th , ... which has developed the AMAS cancer test, is making its ... To date, the test, which is a serum-based in vitro ... emerging as a significant tool in the fight against cancer ... With an estimated 17 million cancer survivors in the ...
Breaking Medicine Technology:MiMedx Announces Record Second Quarter Results 2MiMedx Announces Record Second Quarter Results 3MiMedx Announces Record Second Quarter Results 4MiMedx Announces Record Second Quarter Results 5MiMedx Announces Record Second Quarter Results 6MiMedx Announces Record Second Quarter Results 7MiMedx Announces Record Second Quarter Results 8MiMedx Announces Record Second Quarter Results 9MiMedx Announces Record Second Quarter Results 10MiMedx Announces Record Second Quarter Results 11MiMedx Announces Record Second Quarter Results 12MiMedx Announces Record Second Quarter Results 13MiMedx Announces Record Second Quarter Results 14MiMedx Announces Record Second Quarter Results 15MiMedx Announces Record Second Quarter Results 16MiMedx Announces Record Second Quarter Results 17MiMedx Announces Record Second Quarter Results 18Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2
... safety profile of BSI-201 in ... subjects with advanced solid tumors -, BRISBANE, Calif., ... developing novel cancer therapies,today announced that data supporting its lead ... of Clinical Oncology annual,meeting in Chicago., Findings will be ...
... SGP ), a leader in advancing the ... infection, announced today that data from,several clinical studies ... therapy, as well as boceprevir, the,company,s investigational oral ... annual Digestive Disease Week (DDW) meeting to be ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
(Date:7/28/2014)... British researchers report that an alternative to the traditional ... their experiments, the scientists found that clasping hands transferred ... the other than what is known as a fist ... as a cultural substitute for the firm gripping of ... issue of the American Journal of Infection Control ...
(Date:7/28/2014)... do not divide unless there is enough oxygen present ... other cell types circumvent this rule. Researchers at The ... overrides the cells, warning signals, enabling cancers to continue ... the process, the researchers found that lysosomes the ... decisions. They also uncovered new evidence that certain drugs ...
(Date:7/28/2014)... Michigan (PRWEB) July 28, 2014 The ... Drs. Harris, Birkhill, Wang, Songe and Associates, PC that ... and countless tomorrows to come. , The HBWS ... responsible for more than $2.5 million in donations. Through ... title sponsors for the Oakwood Women’s Healthcare Classic for ...
(Date:7/28/2014)... Lake City, Utah (PRWEB) July 28, 2014 ... protein powders and drinks, announced that it will be ... drink line of products this summer. The additional flavors ... with clean pure taste-free protein , Inspire Pomegranate Razz ... Vanilla - flavor of soft-serve vanilla cone , Bariatric ...
(Date:7/28/2014)... UT Southwestern Medical Center cancer researchers have found ... the activity of a mutated cancer gene common ... SML-8-73-1 (SML), interferes with the KRAS gene, or ... produces proteins called K-Ras that influence when cells ... cells dividing uncontrollably and turning cancerous. These ...
Breaking Medicine News(10 mins):Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Cell's recycling center implicated in division decisions 2Health News:Bariatric Eating Announces Three New Protein Shake Flavors 2Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2
... 2011. Researchers from the University of Maryland School of Medicine ... of exercise and computerized memory training to see if those ... The type of memory that will be examined is known ... and use it in a new way. Many ...
... (DECEMBER 12, 2011) Autism Speaks North America,s ... National Institutes of Health (NIH) in announcing the addition ... a data federation site for the National Database for ... will help create the largest multidisciplinary source of autism ...
... and lethal of all human brain tumors that originate ... followed by both radiation therapy and chemotherapy with temozolomide. ... temozolomide. A team of researchers led by Sameer Agnihotri, ... that the protein APNG can contribute to GBM resistance ...
... - Researchers from Boston University School of Medicine (BUSM) ... receptor (A2bAR) as a possible new therapeutic target against ... cholesterol. The findings, which appear on-line in Circulation ... is a metabolite produced naturally by cells at low ...
... New research from the laboratory of Dr. Elizabeth Leadbetter at ... of vaccines. Dr. Leadbetter,s lab has discovered new properties of ... for enhancing protection against a number of different infections. This ... of the journal Nature Immunology (Vol. 13, pp. ...
... by blocking the export of key control molecules from ... treatment for chronic lymphocytic leukemia (CLL) and other incurable ... at the Ohio State University Comprehensive Cancer Center ... Research Institute (OSUCCC James)., The agent, called KPT-SINE, ...
Cached Medicine News:Health News:Exercise/memory research for Parkinson's 2Health News:Exercise/memory research for Parkinson's 3Health News:Autism Speaks Autism Genetic Resource Exchange joins NIH National Database for Autism Research 2Health News:Autism Speaks Autism Genetic Resource Exchange joins NIH National Database for Autism Research 3Health News:Researchers identify agent responsible for protection against early stages of atherosclerosis 2Health News:Trudeau Institute announces latest discovery in vaccine development 2Health News:Trudeau Institute announces latest discovery in vaccine development 3Health News:Novel export-inhibitor shows promise for treating CLL 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: